1. Home
  2. QLGN vs CETX Comparison

QLGN vs CETX Comparison

Compare QLGN & CETX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLGN
  • CETX
  • Stock Information
  • Founded
  • QLGN 1996
  • CETX 1998
  • Country
  • QLGN United States
  • CETX United States
  • Employees
  • QLGN N/A
  • CETX N/A
  • Industry
  • QLGN Biotechnology: Pharmaceutical Preparations
  • CETX EDP Services
  • Sector
  • QLGN Health Care
  • CETX Technology
  • Exchange
  • QLGN Nasdaq
  • CETX Nasdaq
  • Market Cap
  • QLGN 2.2M
  • CETX 2.3M
  • IPO Year
  • QLGN N/A
  • CETX 1998
  • Fundamental
  • Price
  • QLGN $3.48
  • CETX $1.32
  • Analyst Decision
  • QLGN
  • CETX
  • Analyst Count
  • QLGN 0
  • CETX 0
  • Target Price
  • QLGN N/A
  • CETX N/A
  • AVG Volume (30 Days)
  • QLGN 158.4K
  • CETX 41.2K
  • Earning Date
  • QLGN 05-06-2025
  • CETX 05-13-2025
  • Dividend Yield
  • QLGN N/A
  • CETX N/A
  • EPS Growth
  • QLGN N/A
  • CETX N/A
  • EPS
  • QLGN N/A
  • CETX N/A
  • Revenue
  • QLGN N/A
  • CETX $63,725,617.00
  • Revenue This Year
  • QLGN N/A
  • CETX $19.77
  • Revenue Next Year
  • QLGN N/A
  • CETX $15.00
  • P/E Ratio
  • QLGN N/A
  • CETX N/A
  • Revenue Growth
  • QLGN N/A
  • CETX N/A
  • 52 Week Low
  • QLGN $2.85
  • CETX $1.14
  • 52 Week High
  • QLGN $29.45
  • CETX $4,179.00
  • Technical
  • Relative Strength Index (RSI)
  • QLGN 52.85
  • CETX 42.85
  • Support Level
  • QLGN $3.10
  • CETX $1.16
  • Resistance Level
  • QLGN $4.40
  • CETX $1.53
  • Average True Range (ATR)
  • QLGN 0.40
  • CETX 0.10
  • MACD
  • QLGN 0.05
  • CETX 0.02
  • Stochastic Oscillator
  • QLGN 40.32
  • CETX 35.73

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

About CETX Cemtrex Inc.

Cemtrex Inc is a multi-industry technology company. It has expanded in a range of sectors, including smart technologies, virtual and augmented realities, industrial solutions, and intelligent security system. The company's operating segment includes, Security segment, Industrial Services segment and the corporate segment. The security segment provides end to end security to all industrial, corporate and governmental security via owned subsidiary Vicon. Whereas AIS part Industrial Service Segment is expertise services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly to diversified customers. It generates maximum revenue from the Industrial Service Segment. It geographically operates in USA, UK and India, with maximum of revenue from USA.

Share on Social Networks: